NMD670
Sponsors
NMD Pharma A/S
Conditions
Charcot-Marie-Tooth DiseaseCharcot-Marie-Tooth Disease Type 1 and Type 2Myasthenia GravisMyasthenia Gravis, MuSKSpinal Muscular AtrophyType 3 spinal muscular atrophy
Phase 2
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
CompletedNCT05794139
Start: 2023-09-21End: 2026-05-18Updated: 2026-06-03
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RecruitingNCT06414954
Start: 2024-05-16End: 2026-12-01Target: 84Updated: 2026-08-21
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 over 21 Days in Adult Patients with AChR/MuSK-Ab+ Myasthenia Gravis
RecruitingCTIS2023-507539-40-00
Start: 2024-07-19Target: 59Updated: 2025-11-04
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
CompletedNCT06482437
Start: 2024-09-30End: 2025-11-04Updated: 2025-11-12
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NMD670 over 21 days in Ambulatory Adult Patients with Charcot-Marie-Tooth Disease Type 1 and Type 2
CompletedCTIS2023-507892-23-00
Start: 2024-08-30End: 2025-10-09Target: 52Updated: 2025-09-02
A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy
RecruitingCTIS2024-516321-31-00
Start: 2023-07-07Target: 69Updated: 2025-10-24